To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
about
Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia.Calcitriol regulates angiotensin-converting enzyme and angiotensin converting-enzyme 2 in diabetic kidney disease.Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.
P2860
To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
To RAS or not to RAS? The evid ...... with diabetic kidney disease.
@en
type
label
To RAS or not to RAS? The evid ...... with diabetic kidney disease.
@en
prefLabel
To RAS or not to RAS? The evid ...... with diabetic kidney disease.
@en
P2860
P356
P1433
P1476
To RAS or not to RAS? The evid ...... s with diabetic kidney disease
@en
P2093
Lauren E Odum
P2860
P304
P356
10.1002/PHAR.1232
P407
P577
2013-04-09T00:00:00Z